Thor Medical expands cancer treatment isotope supply agreement

Thor Medical and AdvanCell expanded their strategic supply agreement for Thorium-228, increasing supply by 50% and purchasing commitment from NOK 100m to NOK 150m over five years.

The expansion is supported by Thor Medical's decision to increase AlphaOne plant capacity by up to 40%, financed by a recent capital raise. The increased supply will support AdvanCell's Lead-212 PSMA program for prostate cancer.